ResearcherActive in the last 2 years
Susanna Hegewisch‐Becker
Matched on ORCID iD 0000-0002-8686-2562; OpenAlex author ID A5053589015. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 6
- Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study. Last author DOI 10.1002/ijc.35071↗
- FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in r… First author DOI 10.1002/ijc.34271↗
- Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany. Co-author DOI 10.2217/fon-2022-0141↗
- Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metast… Co-author DOI 10.1002/ijc.31751↗
- Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis fr… Co-author DOI 10.3109/0284186x.2015.1034877↗
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of … Co-author DOI 10.1136/gutjnl-2012-302759↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Norbert Walter Marschner · 3 shared papers, 2019–2024 · strength 0.46
- Paper Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective Germa… DOI 10.1002/ijc.35071↗
- Paper FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to f… DOI 10.1002/ijc.34271↗
- Paper Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with… DOI 10.1002/ijc.31751↗
- Felix W. Friedrich · 1 shared paper, 2022 · strength 0.16
- Tim F. Greten · 2 shared papers, 2013–2015 · strength 0.07
- Paper Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced p… DOI 10.3109/0284186x.2015.1034877↗
- Paper Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advan… DOI 10.1136/gutjnl-2012-302759↗
- Michael Geißler · 2 shared papers, 2013–2015 · strength 0.07
- Paper Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced p… DOI 10.3109/0284186x.2015.1034877↗
- Paper Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advan… DOI 10.1136/gutjnl-2012-302759↗
- Volker Heinemann · 2 shared papers, 2013–2015 · strength 0.07
- Paper Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced p… DOI 10.3109/0284186x.2015.1034877↗
- Paper Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advan… DOI 10.1136/gutjnl-2012-302759↗
- Dirk Waldschmidt · 2 shared papers, 2013–2015 · strength 0.07
- Paper Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced p… DOI 10.3109/0284186x.2015.1034877↗
- Paper Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advan… DOI 10.1136/gutjnl-2012-302759↗
- Stefan Hubert Boeck · 2 shared papers, 2013–2015 · strength 0.07
- Paper Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced p… DOI 10.3109/0284186x.2015.1034877↗
- Paper Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advan… DOI 10.1136/gutjnl-2012-302759↗
- Michael Haas · 1 shared paper, 2015 · strength 0.04
- Stephan Krüger · 1 shared paper, 2015 · strength 0.04
- Dominik Paul Modest · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.